Latest Regulatory News

Brazilian Rare Earths has successfully produced high-purity mixed-rare-earth carbonate and uranium yellowcake from its Monte Alto Project, marking a key milestone in its integrated supply chain ambitions.

ACDC Metals has released a comprehensive scoping study for its Goschen Central project in Victoria, revealing strong economic potential through a two-phase heavy mineral sand and rare earth element operation. The study highlights robust financial metrics and strategic importance in critical minerals supply.

Cochlear Limited has lowered its FY25 earnings guidance due to slower-than-expected sales growth and a sharper decline in Services revenue. Despite this, implant unit growth remains on track, driven by emerging markets.

Hastings Technology Metals appoints Vince Catania as CEO, entrusting him with advancing the Yangibana Rare Earths Project and broader portfolio development.

Marimaca Copper has successfully closed the first tranche of a C$24.4 million private placement, backing its flagship Chilean copper project. The funding round includes significant participation from related parties, setting the stage for accelerated exploration and development.

Nanoveu Limited has locked in a $500,000 funding guarantee through an options underwriting agreement, underpinning its push to commercialise cutting-edge semiconductor and 3D visualisation technologies.

Talga Group has cleared the last regulatory hurdle for its Nunasvaara South graphite mine in Sweden, paving the way for production of battery anode materials critical to the green transition.

Lindian Resources has secured a combined $1.65 million cash inflow from the exercise of unlisted options and a government R&D tax refund, strengthening its financial position for advancing the Kangankunde Rare Earths Project.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Alma Metals Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed information and confirming compliance with ASX rules.

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.

Spartan Resources has dispatched the crucial transaction booklet to shareholders detailing Ramelius Resources’ proposed acquisition, with the Spartan Board unanimously recommending support for the deal.